Poverty-related and neglected diseases - An economic and epidemiological analysis of poverty relatedness and neglect in research and development

Global Health Action

Volumn 8, Issue 1, 2015, Pages

  Von Philipsborn, Peter ^a,b   Steinbeis, Fridolin ^b,c   Bender, Max E ^b,c   Regmi, Sadie ^b,d   Tinnemann, Peter ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Universities Allied for Essential Medicines Europe eV (UAEM)   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Disease burden; Double burden; Global burden of disease; Neglected tropical diseases; Poverty related and neglected diseases; Research and development; Research and development expenditure

Indexed keywords

DEVELOPING COUNTRY; ECONOMIC DEVELOPMENT; HEALTH; HUMAN; MEDICAL RESEARCH; NEGLECTED DISEASES; POVERTY; RISK FACTOR; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; WORLD HEALTH ORGANIZATION; WOUNDS AND INJURIES;

BIOMEDICAL RESEARCH; DEVELOPING COUNTRIES; ECONOMIC DEVELOPMENT; GLOBAL HEALTH; HUMANS; NEGLECTED DISEASES; POVERTY; RISK FACTORS; SOCIOECONOMIC FACTORS; WORLD HEALTH ORGANIZATION; WOUNDS AND INJURIES;

EID: 84925320337     PISSN: None     EISSN: 16549880     Source Type: Journal    
DOI: 10.3402/gha.v8.25818     Document Type: Article

References (35)

1. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet 2013; 382: 1898-955.
2. Remais JV, Zeng G, Li G, Tian L, Engelgau MM. Convergence of non-communicable and infectious diseases in low-and middle-income countries. Int J Epidemiol 2013; 42: 221-7.
3. Evans JA, Shim J-M, Ioannidis JPA. Attention to local health burden and the global disparity of health research. PLoS One 2014; 9: e90147.
4. Drugs for Neglected Diseases Initiative (2012). Medical innovation for neglected patients: important progress over past ten years, but ''fatal Imbalance'' persists. Médecins Sans Frontières. Drugs for Neglected Diseases Initiative. Available from: https://www.aerzte-ohne-grenzen.de/sites/germany/files/attachments/2012-12-13-medical-innovations-for-neglected-patients.pdf [cited 30 October 2014].
5. WHO (2012). Research and development to meet health needs in developing countries: strengthening global financing and coordination. Report of the Consultative Expert Working Group on Research and Development: financing and coordination. WHO. Available from: http://www.who.int/phi/CEWG_Report_5_April_2012.pdf [cited 30 October 2014].
6. Viergever, RF. The mismatch between the health research and development (R&D) that is needed and the R&D that 520 is undertaken: an overview of the problem, the causes, and solutions. Glob Health Action 2013. 6, L22450, doi: http://dx. doi.org/10.3402/gha.v6i0.22450.
7. Pedrique B, Strub-Wourgaft N, Some C, Olliaro P, Trouiller P, Ford N, et al. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. Lancet Glob Health 2013; 1: 371-e9.
8. Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med 2005; 2: e302.
9. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009; 373: 1570-5.
10. Moran M, Guzman J, Ropars A-L, McDonald A, Jameson N, Omune B, et al. Neglected disease research and development: how much are we really spending? PLoS Med 2009; 6: e1000030.
11. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002; 359: 2188-94.
12. Reich MR. The global drug gap. Science 2000; 287: 1979-81.
13. Røttingen J-A, Regmi S, Eide M, Young AJ, Viergever RF, Årdal C, et al. Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory? Lancet 2013; 382: 1286-307.
14. WHO (2013). Draft working paper: a global health R&D observatory-developing a case for its development. WHO. Available from: http://www.who.int/phi/documents/dwp1_global_health_rd_observatory_16May13.pdf [cited 30 October 2014].
15. Rottingen JA, Chamas C. A new deal for global health R&D? The recommendations of the Consultative Expert Working Group on Research and Development (CEWG). PLoS Med 2012; 9: e1001219.
16. Moon S, Bermudez J, 't Hoen E. Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system? PLoS Med 2012; 9: e1001218.
17. WHO (2013). Resolution WHA66.22: follow up of the report of the Consultative Expert Working Group on Research and Development: financing and coordination. Geneva: WHO.
18. WHO (2012). Defining disease types I, II and III-background document provided by the WHO secretariat. Geneva: WHO.
19. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223.
20. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 19 90-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-60.
21. WHO (2001). Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. WHO. Available from: http://whqlibdoc.who.int/publications/2001/924154550x.pdf [cited 30 October 2014].
22. Hotez S, Cohen R, Mimura C, Yamada T, Hoffman S, Patel D. Strengthening mechanisms to prioritize, coordinate, finance, and execute R&D to meet health needs in developing countries. Institute of Medicine, Discussion paper. 2013. Available from: http://iom.edu/-/media/Files/Perspectives-Files/2013/Discussion-Papers/BGH-GlobalHealthRD.pdf [cited 10 January 2014].
23. Moran M, Guzman J, Chapman N, Abela-Oversteegen L, Howard R, Farrell P, et al. Neglected disease research and development: the public divide. G-FINDER Policy Cures; 2013. Available from: http://www.policycures.org/downloads/GF_report13_all_web.pdf [cited 30 October 2014].
24. G-FINDER public search tool: policy cures. 2014. Available from: http://g-finder.policycures.org/gfinder_report/search [cited 1 August 2014].
25. Chakma J, Sun GH, Steinberg JD, Sammut SM, Jagsi R. Asia's ascent-global trends in biomedical R&D expenditures. N Engl J Med 2014; 370: 3-6.
26. Commission on Health Research for Development (1990). Health research-essential link to equity in development. Commission on Health Research for Development. Available from: http://www.cohred.org/publications/open-archive/1990-commission-report/[cited 30 October 2014].
27. WHO. Health R&D demonstration projects 2014. Available from: http://www.who.int/phi/implementation/phi_cewg_meeting/en/[cited 30 October 2014].
28. Young AJ, Terry RF, Røttingen J-A, Viergever RF. Global biomedical R&D expenditures. N Engl J Med 2014; 370: 2451-2.
29. King CH. Parasites and poverty: the case of schistosomiasis. Acta Tropica 2010; 113: 95-104.
30. Fürst T, Silué KD, Ouattara M, N'Goran DN, Adiossan LG, N'Guessan Y, et al. Schistosomiasis, soil-transmitted helminthiasis, and sociodemographic factors influence quality of life of adults in Cô te d'Ivoire. PLoS Negl Trop Dis 2012; 6: e1855.
31. Utzinger J, Becker SL, Knopp S, Blum J, Neumayr AL, Keiser J, et al. Neglected tropical diseases: diagnosis, clinical management, treatment and control. Swiss Med Wkly 2012; 142: w13727.
32. Hotez PJ. NTDs V.2.0: "blue marble health"-neglected tropical disease control and elimination in a shifting health policy landscape. PLoS Negl Trop Dis 2013; 7: e2570.
33. WHO (2010). Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases. WHO. Available from: http://whqlibdoc.who.int/publications/2010/9789241564090_eng.pdf [cited 30 October 2014].
34. Cohen J, Dibner MS, Wilson A. Development of and access to products for neglected diseases. PLoS One 2010; 5: e10610.
35. Viergever RF, Terry RF, Karam G. Use of data from registered clinical trials to identify gaps in health research and development. Bull World Health Organ 2013; 91: 416-25c.